Replies to post #102490 on Biotech Values

[pcrutch]

Regarding their ASCO 2010 abstract(below) on the Phase IIb results on GBM, why was the primary endpoint progression-free rate (PFR) at 5.5 months from first vaccination? Why weren't they interested in overall survival or PFS?

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=53835

http://finance.yahoo.com/news/Interim-Positive-Results-From-bw-761832924.html?x=0&.v=1


Lungman: I wont even bother responding.